BioCentury
ARTICLE | Clinical News

Epacadostat: Phase III started

July 11, 2016 7:00 AM UTC

Incyte and Merck & Co. Inc. (NYSE:MRK, Kenilworth, N.J.) began the double-blind, placebo-controlled, U.S. Phase III ECHO-301 (KEYNOTE-252) trial to evaluate once-daily oral epacadostat in combination...